NiproNIPRO CORPORATION8086東証プライム精密機器FY ending Mar 2026, consolidated, J-GAAP

Nipro FY ending Mar 2026 results

About 79% of Nipro's sales come from Medical treatment related, with Medicine related and PharmaPackaging making up much of the rest.

Out of every ¥100 of sales, about ¥6 is left as operating profit.

Revenue changed +2.5% from the prior year, operating profit +41.5%.

Revenue and profit pattern

Revenue and profit upProfit grew faster

Revenue +2.5% · profit +41.5%, calculated from disclosed figures.

Operating leverage: 16.75× (profit growth ÷ revenue growth)

What changed from last year

FY ending Mar 2025 → FY ending Mar 2026

Revenue: +2.5%¥644.6B → ¥660.5B
Gross profit: +9.1%¥190.9B → ¥208.3B
Operating income: +41.5%¥26.6B → ¥37.6B
Net income attributable to owners: +164.1%¥5.11B → ¥13.5B
Operating cash flow: -20.2%¥68.5B → ¥54.7B
Free cash flow: Loss-¥8.13B → -¥7.63B

Results at a glance

Revenue for the FY ending Mar 2026 was ¥660.5B, up +2.5% from ¥644.6B.
Operating income grew much faster, rising +41.5% from ¥26.6B to ¥37.6B, and net income attributable to owners climbed +164.1% to ¥13.5B.
Cash generation weakened: operating cash flow fell -20.2% to ¥54.7B, and free cash flow stayed negative at -¥7.63B.

What drove the change

In Japan, price revisions and higher shipments of injectables lifted sales; abroad, dialyzer sales grew in the US, China and Europe.
Lower material costs, better plant efficiency and new production lines raised gross profit enough to absorb higher shipping and sales costs.
Net income was also boosted by one-off gains: a gain from taking control of a subsidiary and the sale of a regenerative medicine site.

Things to watch

The pharma packaging business lost money again, hurt by excess inventories of drug glass containers in Europe and the US.
Cuts to drug and device reimbursement prices in Japan and cost control in healthcare worldwide could push selling prices down.
A large share of sales is overseas, so currency swings matter, as do rising prices of petrochemical materials and parts from a limited set of suppliers.

Annual Securities Report, 73rd fiscal year (Apr 2025 – Mar 2026) / 経営者による財政状態、経営成績及びキャッシュ・フローの状況の分析 · Annual Securities Report, 73rd fiscal year (Apr 2025 – Mar 2026) / 事業等のリスク

Where the money goes

FY ending Mar 2025 → FY ending Mar 2026

Where ¥100 of sales goes

For every ¥100 Nipro sells, how much goes where, and how much is kept.

FY ending Mar 2026

Cost of sales: ¥68
SG&A: ¥26
Operating profit: ¥6
Net profit kept: ¥2

Annual margin trends

Gross margin31.5%

Operating margin5.7%

Net margin2.0%

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Which businesses earn the money

Revenue by business segment, and the profit each one keeps.

FY ending Mar 2026

Medical treatment related¥523.6B
79%
Op. margin 10.0%Industry: Medical Devices
Medicine related¥81.1B
12%
Op. margin 14.9%Industry: Pharmaceuticals
PharmaPackaging¥54.7B
8%
Op. margin -2.9%Industry: Glass & Ceramics
Other¥1.13B
0%
Op. margin 83.3%

Profit by segment

※ Segment figures include inter-segment sales and do not sum to the company total

Sources

Show source documents (6)

EDINET (FSA Japan)
有価証券報告書－第73期(2025/04/01－2026/03/31)
ID S100YJLK2026-06-25Open
EDINET (FSA Japan)
有価証券報告書－第72期(2024/04/01－2025/03/31)
ID S100W5PM2025-06-25Open
EDINET (FSA Japan)
有価証券報告書－第71期(2023/04/01－2024/03/31)
ID S100TUDK2024-06-26Open
EDINET (FSA Japan)
有価証券報告書－第70期(2022/04/01－2023/03/31)
ID S100R5KJ2023-06-28Open
EDINET (FSA Japan)
有価証券報告書－第69期(令和3年4月1日－令和4年3月31日)
ID S100OJBW2022-06-28Open
EDINET (FSA Japan)
訂正有価証券報告書－第68期(令和2年4月1日－令和3年3月31日)
ID S100M0A92021-07-15Open

Extracted from XBRL: 57 / Derived from other figures: 2

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open Markdown Share on X Save image